Aptinyx Inc reported $125.29M in Cash and Equivalent for its third fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Acadia Pharmaceuticals ACAD:US $ 94.64M 172.32M
Acorda Therapeutics ACOR:US $ 36.17M 9.55M
Adamas Pharmaceuticals ADMS:US 78.62M 10.17M
Biogen BIIB:US $ 1541.8M 200.2M
Cara Therapeutics CARA:US $ 22.99M 656K
Daiichi Sankyo 4568:JP Y 550054M 197792M
Eli Lilly And LLY:US $ 3788.2M 568.2M
Gw Pharmaceuticals GWPH:US $ 458.1M 28.65M
Halozyme Therapeutics HALO:US $ 491.68M 44.72M
Intra Cellular Therapies ITCI:US $ 106.13M 14.9M
IONIS PHARMACEUT IONS:US $ 1987M 1421.88M
Marinus Pharmaceuticals MRNS:US $ 145.1M 32.61M
Neurocrine Biosciences NBIX:US $ 311.1M 56.9M
Novartis NOVN:VX SF 7211M 2094M
Ultragenyx Pharmaceutical RARE:US $ 197.54M 93.34M
Vertex Pharmaceuticals VRTX:US $ 6275.7M 212.02M